【摘要】 目的:观察三氧化二砷(ATO)联合康力隆治疗骨髓增生异常综合征(MDS)的临床疗效。方法:25例原发性骨髓增生异常综合征-难治性贫血(MDS-RA)患者,其中男15例,女10例,中位年龄39.5岁。治疗方案为ATO10mg/d(儿童酌量),静脉滴注,连用30d,继以每月给药15d,总疗程4个月,同时服用康力隆4～6mg/d。结果:基本缓解8例(32%),部分缓解5例(20%),进步或稳定者5例(20%),无效者7例(28%)。结论:ATO联合康力隆治疗原发性MDS-RA是有效的,且不良反应轻微,总有效率达72%,值得进一步应用总结。更多还原

【Abstract】 Objective:To observe the efficiency of arsenic trioxide (ATO) and stanozolol for the treatment of myelodysplastic syndrome (MDS). Mehtod:Twenty five patients of whom 15 were males 10 females and median age 39.5 years entered into the study. The treatment protocol was as following: ATO 10 mg/d iv for 30 days, followed by 15 days each month and repeated 3 cycles. Stanozolol was given 4~6 mg every day. Result:Eighteen of 25 patients with MDS-RA achieved hematologic improvement and the improvement rate was 72%, No intolerable side effect was observed. Conclusion:The ATO combined with stanozolol in de novo MDS-RA treatment is efficient and is worthwhile to be further investigated and used in clinic.更多还原